vs
Side-by-side financial comparison of Hologic (HOLX) and OCEANEERING INTERNATIONAL INC (OII). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $692.4M, roughly 1.5× OCEANEERING INTERNATIONAL INC). Hologic runs the higher net margin — 17.1% vs 5.2%, a 11.9% gap on every dollar of revenue. On growth, OCEANEERING INTERNATIONAL INC posted the faster year-over-year revenue change (3.6% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $-76.5M). Over the past eight quarters, OCEANEERING INTERNATIONAL INC's revenue compounded faster (1.8% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Oceaneering International, Inc. is a subsea engineering and applied technology company based in Houston, Texas, U.S. that provides engineered services and hardware to customers who operate in marine, space, and other environments.
HOLX vs OII — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $692.4M |
| Net Profit | $179.1M | $36.1M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | — |
| Net Margin | 17.1% | 5.2% |
| Revenue YoY | 2.5% | 3.6% |
| Net Profit YoY | -10.9% | -28.3% |
| EPS (diluted) | $0.79 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $692.4M | ||
| Q4 25 | $1.0B | $668.6M | ||
| Q3 25 | $1.0B | $742.9M | ||
| Q2 25 | $1.0B | $698.2M | ||
| Q1 25 | $1.0B | $674.5M | ||
| Q4 24 | $1.0B | $713.5M | ||
| Q3 24 | $988.0M | $679.8M | ||
| Q2 24 | $1.0B | $668.8M |
| Q1 26 | — | $36.1M | ||
| Q4 25 | $179.1M | $177.7M | ||
| Q3 25 | $187.2M | $71.3M | ||
| Q2 25 | $194.9M | $54.4M | ||
| Q1 25 | $-17.4M | $50.4M | ||
| Q4 24 | $201.0M | $56.1M | ||
| Q3 24 | $178.6M | $41.2M | ||
| Q2 24 | $194.5M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | 19.8% | ||
| Q3 25 | 55.6% | 20.6% | ||
| Q2 25 | 56.3% | 21.3% | ||
| Q1 25 | 37.5% | 20.0% | ||
| Q4 24 | 56.8% | 19.9% | ||
| Q3 24 | 56.4% | 19.3% | ||
| Q2 24 | 55.4% | 18.0% |
| Q1 26 | — | — | ||
| Q4 25 | 22.6% | 9.8% | ||
| Q3 25 | 22.6% | 11.6% | ||
| Q2 25 | 24.9% | 11.3% | ||
| Q1 25 | -0.7% | 10.9% | ||
| Q4 24 | 22.5% | 10.9% | ||
| Q3 24 | 23.3% | 10.5% | ||
| Q2 24 | 24.1% | 9.0% |
| Q1 26 | — | 5.2% | ||
| Q4 25 | 17.1% | 26.6% | ||
| Q3 25 | 17.8% | 9.6% | ||
| Q2 25 | 19.0% | 7.8% | ||
| Q1 25 | -1.7% | 7.5% | ||
| Q4 24 | 19.7% | 7.9% | ||
| Q3 24 | 18.1% | 6.1% | ||
| Q2 24 | 19.2% | 5.2% |
| Q1 26 | — | $0.36 | ||
| Q4 25 | $0.79 | $1.75 | ||
| Q3 25 | $0.84 | $0.71 | ||
| Q2 25 | $0.86 | $0.54 | ||
| Q1 25 | $-0.08 | $0.49 | ||
| Q4 24 | $0.87 | $0.55 | ||
| Q3 24 | $0.75 | $0.40 | ||
| Q2 24 | $0.82 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | $2.5B | $488.8M |
| Stockholders' EquityBook value | $5.2B | $1.1B |
| Total Assets | $9.2B | $2.6B |
| Debt / EquityLower = less leverage | 0.48× | 0.44× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $695.9M | ||
| Q3 25 | $2.2B | $7.0M | ||
| Q2 25 | $1.9B | $7.0M | ||
| Q1 25 | $1.6B | $7.0M | ||
| Q4 24 | $2.0B | $504.5M | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | $488.8M | ||
| Q4 25 | $2.5B | $487.4M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $482.0M | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $5.2B | $1.1B | ||
| Q3 25 | $5.0B | $907.7M | ||
| Q2 25 | $4.8B | $842.1M | ||
| Q1 25 | $4.6B | $773.1M | ||
| Q4 24 | $4.8B | $714.3M | ||
| Q3 24 | $5.1B | $698.0M | ||
| Q2 24 | $5.0B | $651.0M |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $9.2B | $2.7B | ||
| Q3 25 | $9.0B | $2.5B | ||
| Q2 25 | $8.8B | $2.3B | ||
| Q1 25 | $8.5B | $2.3B | ||
| Q4 24 | $8.7B | $2.3B | ||
| Q3 24 | $9.2B | $2.4B | ||
| Q2 24 | $8.9B | $2.3B |
| Q1 26 | — | 0.44× | ||
| Q4 25 | 0.48× | 0.46× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 0.67× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | $-76.5M |
| FCF MarginFCF / Revenue | 20.5% | -11.1% |
| Capex IntensityCapex / Revenue | 1.4% | 2.5% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $238.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $221.1M | ||
| Q3 25 | $355.1M | $101.3M | ||
| Q2 25 | $343.3M | $77.2M | ||
| Q1 25 | $169.4M | $-80.7M | ||
| Q4 24 | $189.3M | $128.4M | ||
| Q3 24 | $367.0M | $91.9M | ||
| Q2 24 | $405.8M | $52.6M |
| Q1 26 | — | $-76.5M | ||
| Q4 25 | $215.2M | $190.7M | ||
| Q3 25 | $341.4M | $77.0M | ||
| Q2 25 | $330.5M | $46.9M | ||
| Q1 25 | $153.9M | $-106.8M | ||
| Q4 24 | $172.5M | $94.5M | ||
| Q3 24 | $350.6M | $67.0M | ||
| Q2 24 | $385.3M | $29.8M |
| Q1 26 | — | -11.1% | ||
| Q4 25 | 20.5% | 28.5% | ||
| Q3 25 | 32.5% | 10.4% | ||
| Q2 25 | 32.3% | 6.7% | ||
| Q1 25 | 15.3% | -15.8% | ||
| Q4 24 | 16.9% | 13.2% | ||
| Q3 24 | 35.5% | 9.9% | ||
| Q2 24 | 38.1% | 4.5% |
| Q1 26 | — | 2.5% | ||
| Q4 25 | 1.4% | 4.6% | ||
| Q3 25 | 1.3% | 3.3% | ||
| Q2 25 | 1.3% | 4.3% | ||
| Q1 25 | 1.5% | 3.9% | ||
| Q4 24 | 1.6% | 4.7% | ||
| Q3 24 | 1.7% | 3.7% | ||
| Q2 24 | 2.0% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 1.24× | ||
| Q3 25 | 1.90× | 1.42× | ||
| Q2 25 | 1.76× | 1.42× | ||
| Q1 25 | — | -1.60× | ||
| Q4 24 | 0.94× | 2.29× | ||
| Q3 24 | 2.05× | 2.23× | ||
| Q2 24 | 2.09× | 1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
OII
Segment breakdown not available.
